Medical Diagnostics

Microbial Medical

Brief Description

Microbial Medical was established to launch novel imaging agents and drugs for diagnosing and treating bacterial and fungal infections, based on a platform technology for chemically linking existing medical compounds with sugars that pathogens consume and human cells reject. The launch products were contrast agents that enable common medical scanners to image infection. The company also planned to produce antibiotics that address antibiotic resistance and have reduced toxicity.

Timeline 2015. Company founded Inventors

Kiyoko Takemiya, Mark Goodman...

Correlia Biosystems, Inc.

Brief Description

Correlia Biosystems develops streamlined assay platforms to reduce the time and cost for quantifying proteins for proteomic and pharmaceutical applications. Our research instruments provide multiplexing capabilities for large protein panels including cytokines and post-translational modifications with unparalleled speed and automation. The company is dedicated to reducing the cost and time to market for candidate drug compounds, and facilitating the access of researchers to large panel protein studies. The company's biomeasurement technology serves the world's top 20...

Vitrichoric, Inc.

Brief Description

Vitrichoric, Inc. develops technology for high-stability supercooling of aqueous solutions or suspensions for the preservation of biological matter.

Timeline 2021. Company founded Inventors

Gabriel Nastase, Boris Rubinsky, Gideon Ukpai

Vitapath Genetics Inc.

Brief Description

VitaPath develops and performs genomic-based tests to determine an individual's need for targeted therapy in certain medical conditions treatable with vitamins. Using our platform, we are leading the exploration of the Vitanome, the subset of information that lies within our genomes that plays a critical role in how we metabolize vitamins, and the commercialization of specific assays that test vitamin-remediable genetic variants. VitaPath's genetic tests are performed by highly skilled professionals in our CLIA-certified, CAP-accredited Clinical Laboratory....

Tenaya Therapeutics

Brief Description

Tenaya Therapeutics is shaping the future of heart disease treatment driven by a mission to discover, develop, and deliver curative therapies that address the underlying drivers of heart disease. Tenaya is developing therapies for rare genetic disorders as well as for more prevalent heart conditions through three platforms: Gene Therapy, Cellular Regeneration, and Precision Medicine. The company was founded by leading cardiology researchers at the Gladstone Institutes and UT Southwestern, and backed by a top-tier syndicate of investors.

Timeline 2016...

Synvivia, Inc.

Brief Description

Synvivia is a synthetic biology company that optimizes cell behavior for gene therapy manufacturing, providing a practical solution for genetically encoded biocontainment. The company is building genetically encoded biocontainment technologies that will enable the widespread use of synthetic biology outside of the laboratory.

The company's technology was developed at UC Berkeley with grants from the NSF and DARPA. The work was published in ACS Synthetic Biology and featured as an Editor’s Choice in Science Magazine. Synvivia has exclusive license to the...

Shrink Technologies, Inc.

BRIEF DESCRIPTION

Shrink Technologies, Inc., based in Carlsbad, California, was acquired by Shrink Nanotechnologies, Inc. on May 29, 2009. Shrink Technologies specializes in developing innovative technologies, particularly focused on metal-enhanced fluorescence (MEF) applications. Their MEF technology, which integrates rapid prototyping methods with metal-fluorescence enhanced immunoassays, significantly enhances the sensitivity of diagnostic assays, making it possible to detect interactions that current methods miss. This technology has broad applications in drug discovery,...

OncoRx Pharmaceuticals, Inc.

Brief Description

OncoRx Pharmaceuticals is an early-stage pharmaceutical company discovering and developing targeted therapies that control the progression of invasive malignant cancer. OncoRx has identified and tested drugs that markedly alter the sustained directional mobility, the uncontrolled cell cycle, and t​​he unrestrained growth and proliferation of intrinsically and acquired therapy-resistant tumors. Unlike non-aggressive primary tumors, the growth, progression and invasiveness of therapy-resistant tumors are not effectively controlled with currently available cancer therapies...

BioScale, Inc.

Brief Description

BioScale developed diagnostic solutions that address critical unmet needs in population health and chronic care. An area of focus has been vulnerable populations such as those with chronic obstructive pulmonary disease, diabetes, and cardiovascular disease. The company's algorithms utilized combinations of blood-based biomarkers for identifying individuals at high risk for severe outcomes. BioScale's rigorous approach to test development included collaborating with leading academic medical centers and validating assays in large, carefully curated cohorts.

Bioscale...

BioAmp Diagnostics

Brief Description

BioAmp develops novel, instrument-free screening and diagnostic tools to identify antibiotic-resistant bacteria in patient samples.

Timeline 2017. Company founded, and participated in the Citris Foundry accelerator program Inventors

Tara DeBoer, Niren Murthy, Jessica Marie Palomino, Lee Woodland Riley